Experimental studies of the combination effects of berberine and puerarin on NASH in vitro
-
摘要: [目的]探讨葛根素、小檗碱联合用药干预非酒精性脂肪性肝炎细胞模型的相关剂量及作用效果。[方法]用500 μmol/L的FFA诱导HepG2细胞24 h,建立NASH细胞模型;用不同浓度的葛根素、小檗碱单药及组合用药干预NASH细胞模型,MTT法检测两种单体对细胞模型的安全药物浓度范围;油红O染色观察细胞内脂肪变;Elisa法检测细胞培养上清液中TNF-α、IL-8及GLUT4水平。[结果]①NASH细胞模型组培养液中TNF-α及IL-8含量明显高于空白对照组,GLUT4含量明显低于空白对照组;②不同浓度葛根素、小檗碱单用及联合用药干预组,随着小檗碱、葛根素单独使用浓度的增加,IL-8、TNF-a水平较模型组明显降低,GLUT4含量显著增加,细胞内红色脂滴减少;单体联合用药后,IL-8、TNF-a、GLUT4水平及细胞内红色脂滴均较单独用药改善明显。[结论]葛根素、小檗碱组合用药在改善细胞病理、TNF-α、IL-8、GLUT4水平方面存在协同作用,其组合用药效果较单独用药效果增强。细胞实验中,基本能够确定在一定范围内,小檗碱与葛根素组合比例在1[BFZ]:40~1[BFZ]:10为佳。Abstract: [Objective] To discuss the combination effects of puerarin and berberine on NASHin vitro.[Methods] Liver cells HepG2 were cultured and induced by FFA to establish NASH model. Then different concentrations of puerarin and berberine combination with different proportions were meanwhile added. MTT was used to detect IL-8,TNF-α,and GLUT4 in supernatant. Oil red O staining was used to observe the adipose cells.[Results] (1)The levels of TNF-α and IL-8 were significantly higher in model group than the control group, while GLUT4 significantly lower than control group. (2)Different concentrations of puerarin and berberine alone and combination in the intervention groups decreased lipid droplets significantly and increased GLUT4 level in a dose-dependent manner, with better results in the combination group than single usage of puerarin and berberine groups. [Conclusion]Combination of puerarin and berberine can improve cellular pathology and influence the levels of TNF-α,IL-8 and GLUT4,showing a synergistic effect.
-
Key words:
- NASH /
- cell model /
- puerarin /
- berberine /
- drug combination
-
-
[1] 萧树东,许国铭主编.中华胃肠病学[M].北京:人民卫生出版社出版,2008,591-597.
[2] POWELL E E,COOKSLEY W G,HANSON R,et al.The natural history of nonalcoholic steatohepatitis:a follow-up study of forty-two patients for up to 21 years[J].Hepatology,1990,11:74-80.
[3] CALDWELL S H,CRESPO D M.The spectrum expanded:cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease[J].J Hepatol,2004,40:578-584.
[4] KASHI M R,TORRES D M,HARRISON S A.Current and emerging therapies in nonalcoholic fatty liver disease[J].Semin Liver Dis,2008,28:396-406.
[5] 蒋树林.非酒精性脂肪性肝病的流行病学和自然史[J].中国全科医学,2007,10(24):2021-2027.
[6] SHIMADA M,HASHIMOTO E,TANIAI M,et al.Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis[J].J Hepatol,2002,37:154-160.
[7] 肖利力.北京地区部分健康人群超声检查结果分析[J].中国国境卫生检疫杂志,2005,28(2):70-71.
[8] SMITH B W,ADAMS L A.Non-alcoholic fatty liver disease[J].Crit Rev Clin Lab Sci,2011,48:97-113.
[9] 丁效蕙,赵景民.非酒精性脂肪性肝炎的发病机制及治疗的研究进展[J].世界华人消化杂志,2005,13(3):371-375.
[10] LASZLO ROMICS,JR.KAREN KODYS,ANGELA DOLANIUC,et al.Diverse Regulation of NF-κB and Peroxisome Proliferator-Activated Receptors in Murine Nonalcoholic fatty liver[J].Hepatology,2004,2:376-384.
[11] WALTER W,MICHALIK L.PPARs at the crossroads of lipid signaling and inflammation[J].Trends Endocrinol Metab,2012,23(7):351-363.
[12] 赵林华,姬航宇,仝小林,等.葛根芩连汤治疗糖尿病理论探讨[J].中华中医药杂志,2012,27(2):280-283.
[13] 王浩,徐明,王思程.葛根芩连汤对溃疡性结肠炎模型大鼠血清Bcl-2、TGF-β1的影响[J]四川中医,2011,29(11):12-14.
[14] 续畅,王允亮,李军祥,等.葛根芩连汤对高脂饮食诱导大鼠非酒精性脂肪性肝炎的影响[J].世界华人消化杂志,2014,22(4):546-552.
[15] Norberto C Chavez-Tapia,Natalia Rosso,Claudio Tiribelli.Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease[J].BMC Gastroenterol,2012,12:20-20.
[16] 高风英.葛根素药理作用的研究进展[J].中草药,2003,34(12):7-8.
[17] 李波,朱维良,陈凯先.小檗碱及其衍生物的研究进展[J].药学学报,2008,43(8):773-787.
[18] FARRELL G C,van ROOYEN D,GAN L,et al.NASH is an Infl ammatory Disorder:Pathogenic,Prognostic and Therapeutic Implications[J].Gut Liver,2012,6:149-171.
[19] 郭启煜.胰岛素受体与胰岛素抵抗[J].海军总医院学报,1999,12(2):88-90.
[20] 宋春宇,毕会民.葛根素对大鼠胰岛素刺激下骨骼肌细胞膜GLUT4蛋白含量的影响[J].中国中药杂志,2004,29(2):172-175.
-
计量
- 文章访问数: 47
- PDF下载数: 19
- 施引文献: 0
下载: